In 1993, we described an English family with beta-thalassaemia that was not linked to the beta-globin locus. Whole genome sequence analyses revealed potential causative mutations in 15 different genes, of which 4 were consistently and uniquely associated with the phenotype in all 7 affected family members, also confirmed by genetic linkage analysis. Of the 4 genes, which are present in a centromeric region of chromosome 1, ASH1L was proposed as causative through functional mRNA knock-down and chromatin-immunoprecipitation studies in human erythroid progenitor cells. Our data suggest a putative role for ASH1L (Trithorax protein) in the regulation of globin genes.
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Beta-thalassaemia is among the most common monogenic disorders worldwide. Over 200 mutations down-regulating the bglobin gene (HBB) causing b-globin deficiency have been characterized; the majority of these mutations are cis-acting and reside within HBB itself, or within its immediate flanking sequences (Giardine et al, 2011; Thein, 2013) . Several rare trans-acting mutations have also been described, including mutations affecting GATA1 on the X chromosome, KLF1 on chromosome 19 and those affecting XPD protein, or implicated from family studies (Thein, 2013) .
In 1993, we described one such family of English descent with b -thalassaemia trait phenotype that was not linked to the HBB locus (Thein et al, 1993) . Further genetic analyses revealed 4 candidate genes (LRIG2, ANKRD35, NUP210L and ASH1L), which were inherited as a block spanning the centromere on chromosome 1. Of the 4 genes, 2 were expressed in erythroid progenitors, but only ASH1L correlated with differentiation of human erythroid progenitor cells (hEPCs) and HBB expression. Our data suggest a role for ASH1L, a methyl transferase protein and member of the trithorax short report (Trx) family, in regulation of the HBB gene and as a potential modifier of beta-thalassaemia severity.
Material and methods
Patient samples were sent for work-up of unexplained anaemia.
Genetic analyses
We performed whole genome sequence (WGS) analysis in 2 affected and 2 unaffected members of the family (Data S1, and Figure S1 ). Filtering approaches included: exclusion of variants that are not shared by affected members, and absent in unaffected members; exclusion of non-coding variants and non-rare coding variants (frequency > 0Á5%) (Ott et al, 2015) . Following the dominant mode of inheritance suggested by the familial segregation, we found mutations in 15 genes [four on chromosome (chr)1, four on chr3, one on chr6, one on chr8, one on chr10, one on chr19, and three on chr20] (Table SI) . Using Sanger sequencing we screened 27 family members spanning three generations, including the four individuals that were subjected to WGS, for the presence of these 15 genetic variants. This revealed firstly, that all 15 variants were present in the two affected, and absent in the two unaffected WGS individuals, confirming that these mutations were not artefacts of the WGS assemblies; and secondly, that four genetic variants were consistently and uniquely present in all seven affected family members (Table SII) .
Linkage analysis
Two-point linkage analysis was performed with MLINK (Lathrop et al, 1984) . Marker genotypes were obtained from Sanger sequencing data (seven affected and 20 unaffected individuals), thalassaemia phenotypes were as previously described (Thein et al, 1993) . The model assumed autosomal-dominant inheritance of the b thalassaemia trait with complete penetrance and phenocopy rate 0Á000001. The ASH1L variant (T>C, dbSNP rs151028549) identified in the English family is extremely rare with a population frequency of 0Á001, present only in British and Spanish populations (http:// www.ncbi.nlm.nih.gov/variation/tools/1000genomes/?chr=NC_ 000001.10&from=155447318&to=155448318&mk=155447818: 155447818|rs151028549&gts=rs151028549). The minor allele, consisting of a block spanning the centromere on chromosome 1 containing LRIG2, ANKRD35, NUP210L and ASH1L genes, was assumed to be extremely rare, and the population frequency was set to 0Á00001.
Logarithm of odds (LOD) scores were calculated for recombination rates (Θ) of 0Á5 (no linkage), 0 (marker is the causative variant), 0Á01, 0Á02, 0Á03, 0Á04 and 0Á05 between marker and causative variant. The block on chromosome 1 displays a LOD score of 3Á01 for a Θ of 0, giving evidence for linkage between the rare sequence variants and the causative variant acting in this family (Table SIII) .
Gene expression and chromatin immunoprecipitation
hEPCs were cultured from buffy coats from healthy adults using a two-phase culture system (van den Akker et al, 2010). K562 cells were maintained in Dulbecco's Modified Eagle medium and RPMI medium, respectively, supplemented with 10% fetal calf serum and penicillin/streptomycin.
shRNA constructs against ASH1L were obtained from The RNAi Consortium (TRC) shRNA library (Sigma, St Louis, MO, USA). Four different shRNA lentiviruses were tested in K562 cells, of which 2 (referred to as shRNA1 and shRNA2) were retained for further experiments. A non-targeting TRC shRNA was used as control. hEPCs were transduced on Phase 2 Day 2 (P2D2) culture, selected in medium supplemented with puromycin, and processed for gene analysis on Phase 2 Day 8 (P2D8).
Binding of ASH1L and histone H3 trimethylated-lysine 4 (H3K4me3) at HBB and HBA promoter regions in K562 and hEPCs was evaluated following previously described procedures. hEPCs at P1D5, P2D4 and P2D8 were selected for chromatin immunoprecipitation-quantitative polymerase chain reaction (ChIP-qPCR) analysis. Cells were crosslinked using 1% formaldehyde and the chromatin sonicated using a Covaris (Woburn, MA, USA) E2000 machine. Quantitation of immunoprecipitated samples was performed by real-time PCR using SYBR green dye on a Prism 7900H instrument (ABI, Foster City, CA, USA).
Results and discussion
Linkage analysis in conjunction with WGS (Ott et al, 2015) has allowed us to narrow potential trans-acting candidates for the beta-thalassaemia phenotype to 4 genes. Candidacy of at low levels (Wang et al, 2012) . ASH1L encodes a protein from the Trithorax family and acts as a histone methyl transferase. It has been found to be recruited at the transcribed portion of the mouse beta-major globin gene of G1E cells under GATA-1-mediated erythroid differentiation and is absent in undifferentiated cells (Gregory et al, 2007) . Both LRIG2 and ASH1L are expressed during differentiation of hEPCs; LRIG2 being the less expressed of the two genes ( Figure S2A ). While expression of LRIG2 remained at low levels throughout erythroid differentiation, ASH1L expression clearly increased, reaching a peak at day 6 of erythroid differentiation, just before the rise in globin gene expression ( Figure S2A,B) . Based on the ASH1L expression profile during erythroid differentiation and its known functions, it was selected for further studies.
shRNA1 and shRNA2 induced a decrease in 60% and 80%, respectively, of ASH1L mRNA expression in transduced hEPCs ( Fig 1A) and the differentiation of the hEPCs does not appear to be affected ( Fig 1B) . Overall, a decrease in HBB, HBA and HBG expression was observed on suppression of ASH1L with shRNA1 and shRNA2 compared to the TRC hEPCs (Fig 1 C-E) , but there was minimal change in the HBA/non-HBA ratio on ASH1L repression (Fig 1F) .
We performed ASH1L ChIP on K562 cells and on hEPCs at different stages of erythroid differentiation. K562 cells appear as a good control for evaluating ASH1L enrichment in the HBB promoter as they do not express b-globin and express HBA in a low quantity. In K562 cells, there was no enrichment of ASH1L to the HBB promoter but a slight enrichment was observed for the HBA promoter (Fig 2A) .
hEPCs at P1D5, P2D4 and P2D8 were selected for ChIP-qPCR analysis as both HBA and HBB are expressed but at different levels in these cells. In P1D5 hEPCs, there is no expression of HBB and no evidence of ASH1L binding to the HBB Tables SIV and SV. promoter ( Fig 2B) . With differentiation, there is increased binding of ASH1L to the HBB and HBA promoters in both P2D4 and P2D8 cells (Fig 2C and D) . On repression of ASH1L with shRNA1, ASH1L binding to the HBA and HBB promoters is lost (Fig 2E) ; it is still present in the TRC transduced hEPCs (Fig 2F) . To further investigate the impact of ASH1L repression, we assessed H3K4me3 enrichment at the HBA and HBB promoters in K562 and P2D8 cells transduced with TRC or ASH1L shRNA1. In K562, H3K4me3 enrichment is observed at the HBA promoter with modest enrichment at the HBB promoter ( Fig 2G) . Upon repression of ASH1L with shRNA1, H3K4me3 enrichment at the HBA and HBB promoters was reduced by a third compared to the TRC P2D8 hEPCs (Fig 2H and I) . Our data support the genetic studies that suggest ASH1L as a putative candidate underlying the beta-thalassaemia in this English family. ASH1L is associated with the active HBB promoter in differentiating human erythroid precursor cells, just as in the mouse. However, the imbalanced globin ratio observed in the family was not replicated in our experiments. Compared to the missense mutation observed in the English family, we propose that 60-80% silencing of ASH1L expression has a larger impact on the entire genome as ASH1L protein is associated with a large number of active genes in the cells (Gregory et al, 2007) .
The ASH1L variant within exon 3, replaces Glycine for Arginine, introducing a larger and charged amino acid at location 1615, in a serine rich domain before the SET domain. The human ASH1L gene, like its Drosophila counterpart, encodes a SET domain-containing trithorax protein with a histone methyl-transferase activity that can associate with actively transcribed loci, including at several HOX genes (Gregory et al, 2007; Tanaka et al, 2008 Tanaka et al, , 2011 . The ASH1L SET domain was reported to have intrinsic H3K36 dimethyltransferase activity using in-vitro biochemical assays (Tanaka et al, 2007; Yuan et al, 2011) and methylates H3K4 in vitro (Gregory et al, 2007) . Here, we established that enrichment of H3K4me3 at HBB and HBA promoters is reduced upon repression of ASH1L. The shRNA experiments may have also differential effects on the HBA and HBB promoters because they are fundamentally different promoters, a being part of a methylation-free island with many CG sequences (Quante & Bird, 2016) . Further studies on the role of ASH1L and its role in beta globin regulation will clarify the contribution of this gene to globin gene regulation.
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